These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38387399)

  • 1. Multi-target rational design and synthesis of novel diphenyl-tethered pyrazolopyrimidines targeting EGFR and topoisomerase II with potential DNA intercalation and apoptosis induction.
    Gaber AA; Abo Elmaaty A; Sharaky M; Mosa AA; Yahya Abdullah Alzahrani A; Shaaban S; Eldehna WM; Al-Karmalawy AA
    Bioorg Chem; 2024 Apr; 145():107223. PubMed ID: 38387399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacophore-based, rationale design, and efficient synthesis of novel tetrahydrobenzo[b]thiophene candidates as potential dual Topo I/II inhibitors and DNA intercalators.
    Nofal HR; Al-Karmalawy AA; Elmaaty AA; Ismail MF; Ali AK; Abbass EM
    Arch Pharm (Weinheim); 2024 Sep; 357(9):e2400217. PubMed ID: 38864845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel quinazolin-2-yl 1,2,3-triazole hybrids as promising multi-target anticancer agents: Design, synthesis, and molecular docking study.
    El Hamaky NFM; Hamdi A; Bayoumi WA; Elgazar AA; Nasr MNA
    Bioorg Chem; 2024 Jul; 148():107437. PubMed ID: 38749114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.
    Lamie PF; El-Kalaawy AM; Abdel Latif NS; Rashed LA; Philoppes JN
    Eur J Med Chem; 2021 Mar; 214():113222. PubMed ID: 33545637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, efficient synthesis, docking studies, and anticancer evaluation of new quinoxalines as potential intercalative Topo II inhibitors and apoptosis inducers.
    Abbass EM; Khalil AK; Mohamed MM; Eissa IH; El-Naggar AM
    Bioorg Chem; 2020 Nov; 104():104255. PubMed ID: 32927130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel topoisomerase II/EGFR dual inhibitors: design, synthesis and docking studies of naphtho[2',3':4,5]thiazolo[3,2-
    Mourad MAE; Abo Elmaaty A; Zaki I; Mourad AAE; Hofni A; Khodir AE; Aboubakr EM; Elkamhawy A; Roh EJ; Al-Karmalawy AA
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2205043. PubMed ID: 37165800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, molecular modeling, in vivo studies and anticancer activity evaluation of new phthalazine derivatives as potential DNA intercalators and topoisomerase II inhibitors.
    El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Khalifa MM; Belal A; Rashed M; El-Sharkawy A; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; Eissa IH
    Bioorg Chem; 2020 Oct; 103():104233. PubMed ID: 32882440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, docking, and anticancer evaluations of new thiazolo[3,2-
    El-Zoghbi MS; El-Sebaey SA; Al-Ghulikah HA; Sobh EA
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2175209. PubMed ID: 36776024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors.
    El-Adl K; El-Helby AA; Sakr H; Elwan A
    Bioorg Chem; 2020 Dec; 105():104399. PubMed ID: 33113414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and antiproliferative evaluation of new quinoxalines as potential DNA intercalators and topoisomerase II inhibitors.
    Eissa IH; Metwaly AM; Belal A; Mehany ABM; Ayyad RR; El-Adl K; Mahdy HA; Taghour MS; El-Gamal KMA; El-Sawah ME; Elmetwally SA; Elhendawy MA; Radwan MM; ElSohly MA
    Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900123. PubMed ID: 31463953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel fused imidazotriazines acting as promising top. II inhibitors and apoptotic inducers with greater selectivity against head and neck tumors: Design, synthesis, and biological assessments.
    Al-Karmalawy AA; Rashed M; Sharaky M; Abulkhair HS; Hammouda MM; Tawfik HO; Shaldam MA
    Eur J Med Chem; 2023 Nov; 259():115661. PubMed ID: 37482023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel triazolophthalazine derivatives as DNA intercalators and topoisomerase II inhibitors.
    Sakr H; Ayyad RR; El-Helby AA; Khalifa MM; Mahdy HA
    Arch Pharm (Weinheim); 2021 Jun; 354(6):e2000456. PubMed ID: 33554352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and
    Khalifa MM; Al-Karmalawy AA; Elkaeed EB; Nafie MS; Tantawy MA; Eissa IH; Mahdy HA
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):299-314. PubMed ID: 34894955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of thiadiazolo-carboxamide bridged β-carboline-indole hybrids: DNA intercalative topo-IIα inhibition with promising antiproliferative activity.
    Tokala R; Sana S; Lakshmi UJ; Sankarana P; Sigalapalli DK; Gadewal N; Kode J; Shankaraiah N
    Bioorg Chem; 2020 Dec; 105():104357. PubMed ID: 33091673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A rational design strategy of the novel topoisomerase II inhibitors for the synthesis of the 4-O-(2-pyrazinecarboxylic)-4'-demethylepipodophyllotoxin with antitumor activity by diminishing the relaxation reaction of topoisomerase II-DNA decatenation.
    Zhao W; Chen L; Li HM; Wang DJ; Li DS; Chen T; Yuan ZP; Tang YJ
    Bioorg Med Chem; 2014 Jun; 22(11):2998-3007. PubMed ID: 24775914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel pyrazole-based COX-2 inhibitors as potential anticancer agents: Design, synthesis, cytotoxic effect against resistant cancer cells, cell cycle arrest, apoptosis induction and dual EGFR/Topo-1 inhibition.
    Halim PA; Sharkawi SMZ; Labib MB
    Bioorg Chem; 2023 Feb; 131():106273. PubMed ID: 36444790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel ciprofloxacin hybrids using biology oriented drug synthesis (BIODS) approach: Anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis, topoisomerase II inhibition, and antibacterial activity.
    Kassab AE; Gedawy EM
    Eur J Med Chem; 2018 Apr; 150():403-418. PubMed ID: 29547830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel rigid analogs of 2-naphthol with potent anticancer activity through multi-target topoisomerase I & II and tyrosine kinase receptor EGFR & VEGFR-2 inhibition mechanism.
    El-Mawgoud HKA; Fouda AM; El-Nassag MAA; Elhenawy AA; Alshahrani MY; El-Agrody AM
    Chem Biol Interact; 2022 Mar; 355():109838. PubMed ID: 35123995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel 6,7,8-trihydrobenzo[6',7']cyclohepta[2',1'-e]pyrazolo[2,3-a]pyrimidine derivatives as Topo IIα inhibitors with potential cytotoxic activity.
    Farghaly TA; Gaber Abdulwahab H; Medrasi HY; Al-Sheikh MA; Katowah DF; Alsaedi AMR
    Bioorg Chem; 2022 Nov; 128():106043. PubMed ID: 36058118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New pyranopyrazole based derivatives: Design, synthesis, and biological evaluation as potential topoisomerase II inhibitors, apoptotic inducers, and antiproliferative agents.
    Sobh EA; Kassab AE; El-Khouly EA; S A Hassan M
    Bioorg Chem; 2024 Mar; 144():107158. PubMed ID: 38301427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.